Literature DB >> 6340622

Increased fibrinolysis and amyloidosis.

H Liebman, M Chinowsky, J Valdin, G Kenoyer, D Feinstein.   

Abstract

We studied three patients with amyloidosis who had a significant hemorrhagic disorder secondary to increased fibrinolysis. In two of the three patients, bleeding was one of the major initial problems; in the other patient, bleeding occurred later in the course of the disease. All three patients were men with primary or myeloma-associated amyloidosis (ie, immunoglobulin-related or AL). None of the patients had significantly impaired liver function at the time of the diagnosis of increased fibrinolysis. At admission, fibrinogen levels were 60, 170, and 90 mg/dL in the three patients. All three patients had short euglobulin clot lysis times (less than 30 minutes) and evidence of in vitro clot lysis. One patient appeared to respond to aminocaproic acid (EACA). In patients with amyloidosis and bleeding, fibrinolytic tests should be done; in patients with increased fibrinolysis, a diagnosis of amyloidosis should be considered.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6340622

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  6 in total

1.  Reversible functional asplenia and subcapsular liver hematoma--two distinctive manifestations of amyloidosis.

Authors:  E Levy-Lahad; D Steiner-Salz; N Berkman; R Chisin; P Levensart; E Leitersdorf
Journal:  Klin Wochenschr       Date:  1987-11-16

2.  Systemic AL amyloidosis with disseminated intravascular coagulation associated with hyperfibrinolysis.

Authors:  Toru Takahashi; Munehiro Suzukawa; Masaru Akiyama; Katsuhiro Hatao; Yukinori Nakamura
Journal:  Int J Hematol       Date:  2008-05       Impact factor: 2.490

Review 3.  Clinical disorders of fibrinolysis: a critical review.

Authors:  R B Francis
Journal:  Blut       Date:  1989-07

4.  Coagulation and fibrinolytic features in AL amyloidosis with abnormal bleeding and usefulness of tranexamic acid.

Authors:  Masahisa Arahata; Hiroyuki Takamatsu; Eriko Morishita; Yasuko Kadohira; Shinya Yamada; Akitada Ichinose; Hidesaku Asakura
Journal:  Int J Hematol       Date:  2020-01-03       Impact factor: 2.490

Review 5.  Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.

Authors:  T E Clark; N Edom; J Larson; L J Lindsey
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

Review 6.  Cutaneous manifestations of monoclonal gammopathy.

Authors:  Jean-Sebastien Claveau; David A Wetter; Shaji Kumar
Journal:  Blood Cancer J       Date:  2022-04-11       Impact factor: 11.037

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.